Coeptis Therapeutics Holdings Inc
COEP
Company Profile
Business description
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Contact
105 Bradford Road
Suite 420
WexfordPA15090
USAT: +1 724 934-6467
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,467.00 | 4.40 | 0.05% |
| CAC 40 | 7,856.28 | 112.53 | 1.45% |
| DAX 40 | 23,568.39 | 69.07 | 0.29% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,601.09 | 46.29 | 0.54% |
| HKSE | 23,549.46 | 681.72 | 2.98% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
| SSE Composite Index | 3,369.24 | 27.25 | 0.82% |